Virology Specimen Collection Market Size, Share & Industry Analysis By Product (Blood Collection Kits, Viral Transport Media, Specimen Collection Kits, and Swabs), By Sample (Blood, Nasopharyngeal Sample, Throat Sample, Cervical Sample, Oral Sample, and Others), By End-user (Hospitals & Clinics, Diagnostic Laboratories, and Others), and Regional Forecast, 2026-2034

The global virology specimen collection market is experiencing significant growth, primarily driven by the increasing demand for point-of-care testing due to the substantial burden of viral infections worldwide. This is encouraging key players to develop advanced products such as 3D-printed nasopharyngeal swabs. Moreover, the growing awareness of early diagnosis of viral infections is also increasing the demand for viral specimen collection products.

Virology Specimen Collection Market Driver

Rising Incidence of Viral Infections to Fuel the Market Growth

Over the past few years, the higher rates of viral illnesses such as influenza and RSV and bacterial infections, including staphylococcus, chlamydia, and various STIs, are fueling the demand for diagnostic products such as viral specimen collection kits. Moreover, the emergence of MERS-CoV, SARS-CoV, and, most notably, COVID-19 has further increased the demand for nasopharyngeal swabs and related media due to routine testing, thereby driving market growth.

• For instance, according to CDC estimates, there were at least 35.0 million flu cases during the 2023–2024 season, leading to an increased usage of swabs and transport media.

Get comprehensive study about this report by, Download free sample copy

According to data published by the National Center for Biotechnology Information (NCBI) in March 2021, from 2017 to 2019, the U.S. reported the highest number of influenza cases at 749,472, followed by China with 302,126, Canada with 154,082, the U.K. with 106,087, and Norway with 71,727 cases during this period.

Virology Specimen Collection Market Restraint

Degradation of Sample Efficiency and False Detection to Hinder Demand for Viral Specimen Collection

Several challenges, such as the improper collection, transportation, and storage conditions, is leading to the degradation of viral specimens, adversely affecting the accuracy and reliability of diagnostic test results. Moreover, the temperature variations or extended storage times are further compromising specimen integrity and complicating diagnosis. Furthermore, a low pathogen produces false negatives, increasing the risk of virus spread, restricting the reliance on nasopharyngeal samples, and hindering the market growth.

Virology Specimen Collection Market Opportunity

Increasing Demand for At-home Testing to Offer Lucrative Opportunities

Recently, there has been an increasing consumer preference for at-home viral specimen collection solutions, due to their user-friendliness and the ability to avoid visits to healthcare facilities during outbreaks of viral infections. This is encouraging key players to launch at-home viral specimen collection kits and regulatory authorities are also increasing approval for such products, offering lucrative opportunities for market growth.

• For instance, in November 2020, the FDA authorized the Lucira COVID-19 All-In-One test kit as the first fully self-administered COVID-19 molecular test for rapid results at home.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence of Key Viral Diseases, by Key Countries/Region, 2025
• Advancements in Viral Specimen Collection Products
• Key Industry Developments - (Mergers, Acquisitions & Partnerships, and Others)

Analysis by Product

Based on product, the market for virology specimen collection is subdivided into blood collection kits, viral transport media, specimen collection kits, and swabs.

The blood collection kits segment is expected to account for the largest market share during the forecast period. The growth is primarily driven by its widespread applications in hematology, biochemistry, and infectious disease testing. Moreover, the increasing demand from hospitals and diagnostic labs is stimulating key players to launch new products.

• For instance, in August 2023, Nightingale Health introduced a remote blood collection kit for medical research and clinical trials, enabling participants to self-collect blood samples with the Velvet device.

Analysis by Sample

The market, by sample, is divided into blood, nasopharyngeal sample, throat sample, cervical sample, oral sample, and others.

The blood segment is expected to hold a major share during the forecast period. Blood is a vital component required for detecting viral infections, which drives high test volumes through blood collection kits globally, thereby hindering the segment’s growth.

Analysis by End-user

In terms of end-user, the market is categorized into hospitals & clinics, diagnostic laboratories, and others.

The hospitals & clinics companies segment held the largest market share in 2025. The segment’s growth is attributed to the patient's high preference for diagnosing STDs such as chlamydia and respiratory infections, including influenza, RSV, and COVID-19, in hospitals & clinics, which provides accurate results. This is expected to increase the utilization of virology specimen collection in hospitals.

• For instance, according to an article published by the Cleveland Clinic in February 2022, nasal swab tests for viruses such as SARS-CoV-2 yield more accurate results when performed by a trained medical professional.

Regional Analysis

Request for Customization   to gain extensive market insights.

The market, in terms of region, has been studied across North America, Latin America, Europe, the Middle East & Africa, and Asia Pacific.

North America held the largest global market share for virology specimen collection in 2025. The region’s growth is attributed to an increase in molecular assays and RT-PCR tests for viral diseases such as influenza, which involves the collection of nasopharyngeal samples. Furthermore, this surge in molecular assays and RT-PCR tests is propelled by recommendations from healthcare organizations in the region, further driving the demand for virology specimen collection.

• For instance, in November 2025, the Infectious Diseases Society of America (IDSA) recommended using RT-PCR or other molecular assays to detect influenza viruses in respiratory specimens of hospitalized patients.

Asia Pacific is projected to expand at the fastest CAGR during the forecast period. The growth is attributed to increasing investments by key players in the research and development of new tests for the detection of viral diseases, which involve the use of virology specimen collection products, such as kits and swabs.

Key Players Covered

Major players, including Copan Diagnostics Inc., BD, and Puritan Medical Products, dominate the global virology specimen collection market. These companies are further focusing on the development of innovative products and expanding into emerging countries to hold a substantial market share.

The report includes the profiles of the following key players:

• Copan Diagnostics Inc. (U.S.)
• BD (U.S.)
• Puritan Medical Products (U.S.)
• Medical Wire & Equipment (U.K.)
• HiMedia Laboratories (India)
• Hardy Diagnostics (U.S.)
• Cardinal Health (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• AdvaCare Pharma (China)
• VIRCELL S.L. (Spain)

Key Industry Developments

• December 2024: BD and Babson Diagnostics launched an innovative fingertip blood collection and testing technology for use across U.S. health systems, enabling test results from as few as six drops of blood collected from a patient's finger.
• July 2020: Microbrush launched sterilized nasopharyngeal test swabs in medical-grade packaging to meet the growing demand for COVID-19 testing.